PMCID

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients

Retrieved on: 
Thursday, November 2, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Alzheimer's disease, Plasma, AFL, PD, Duarte de Meneses, 3rd Count of Viana, Biomarker, Level, Human, Pathology, Hippocampal sclerosis, Inflammation, Huntingtin, Goate, Mitchell, Dave Senjem, Mitsutake Hikoshichi, White, TAR, Disease, A, GFAP, Nerve, PMCID, S, PMID, Frontotemporal lobar degeneration, Patient, Experimental & Molecular Medicine, YM, Parkinson's disease, Whitwell, Dietary supplement, Medical imaging, Hospital, TDP43

“We are pleasantly surprised to see a statistically significant drop in TDP43 levels in just 10 patients and to see a strong trend in GFAP and NfL.

Key Points: 
  • “We are pleasantly surprised to see a statistically significant drop in TDP43 levels in just 10 patients and to see a strong trend in GFAP and NfL.
  • To our knowledge this is the first time that a drug reduces the levels of TDP43 in humans, specifically here in PD patients,” said Dr. Maccecchini.
  • “These biomarker data not only corroborate the mechanism of actions of buntanetap, but also provide a new way to stratify patients and understand their disease pathology.
  • TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration.

New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues

Retrieved on: 
Monday, October 9, 2023
Page, Doctor of Philosophy, Anxiety, Cognitive behavioral therapy, Cerebrovascular disease, Sleep, Sleep medicine, Nation, Therapy, Psychology, Ageing, University, Dave's Picks Volume 38, Digital, Comorbidity, Disease, Cancer, Randomized controlled trial, Brain damage, Spectrum, Insomnia, Meta-analysis, DSM-IV codes, Journal of Affective Disorders, Research, Depression, SAN, Survivor, RCT, CBT, Nuffield Department of Population Health, ASCO, WSO, PMID, Disability, Systematic review, Canadian International Council, PMCID, Neurorehabilitation and Neural Repair, University of Oxford, Patient, Pharmaceutical industry, Nursing, Dietary supplement, Sleepio, Stroke

SAN FRANCISCO and OXFORD, England, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Big Health, the leader in digital therapeutics for the most common mental health conditions, announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors. 

Key Points: 
  • Digital cognitive behavioral therapy (dCBT) has long been evidenced as an effective treatment for insomnia and anxiety — key findings from these studies provide new insights into Sleepio's impact.
  • In a separate study among stroke survivors, 71% achieved remission using Sleepio compared to 30% of control participants.
  • Individuals with insomnia are three times more likely to develop anxiety than healthy sleepers.
  • [1] Additionally, comorbid insomnia and anxiety are associated with greater severity of both conditions — as well as increased symptoms of depression and poorer physical health.

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Tuesday, October 3, 2023
Well, Vaccine, Interim, KOL, PMID, Biotechnology, ICI, PDSB, Nivolumab, Head, Pembrolizumab, Survival, Infection, Clinical trial, OS, Cancer, Food and Drug Administration, Burtness, Squamous-cell carcinoma, Cetuximab, PFS, Neck, EDT, Doctor of Philosophy, ASCO, IL12, Investigational New Drug, MD, Patient, HNSCC, HPV, Webcast, Knowledge, PMCID, Recurrence, Data monitoring committee, FDA, IND, ORR, DMC, Food, Safety, Pharmaceutical industry, Birth control

Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI1.

Key Points: 
  • Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI1.
  • VERSATILE-002 is investigating two patient populations whose cancer has returned or spread – ICI naïve and ICI refractory.
  • The ICI naïve group had not responded to standard-of-care treatments but had not yet been treated with an ICI.
  • A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer.

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Medical Devices, Health Technology, Other Science, Science, Biotechnology, PROMIS, Journal of Clinical Oncology, United States National Library of Medicine, Prostate, LDT, PMID, BJU International, AIM, National Prostate Health Month, University, Prostate cancer, Abner Doble, Hospital, TRUS, Section, Cancer, UK2, OBD, Large intestine, Mortality, Lung, Penn Presbyterian Medical Center, Protection, MRI, Journal, Patient, Risk, Medicine, BMJ, PSE, Movember, PMCID, NHS, Erectile dysfunction, Death, PSA, News, Biopsy, Dairy, Medical imaging, Urology, Lancet

The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.

Key Points: 
  • The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.
  • It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness month," said Dr Jon Burrows, OBD's Chief Executive Officer.
  • Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication, Journal of Clinical Oncology [online], 28:15.
  • Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Retrieved on: 
Tuesday, September 12, 2023
Cognition, Central nervous system, Therapy, Research, Doctor of Philosophy, Alzheimer's disease, Dementia, Amyloid, Patient, SAN, Synapse, PMCID, Ageing, NIH, Memory, Foundation for the National Institutes of Health, Breast cancer, Prostate cancer, Pharmaceutical industry

The new $3 million grant titled “Development of a Novel, Regenerative Therapy to Reverse Synapse Loss in Alzheimer's Disease” will continue to support the development of SPG302, a patent-protected compound designed by Spinogenix to help restore the brain connections and functions lost in Alzheimer’s disease and related neurodegenerative disorders.

Key Points: 
  • The new $3 million grant titled “Development of a Novel, Regenerative Therapy to Reverse Synapse Loss in Alzheimer's Disease” will continue to support the development of SPG302, a patent-protected compound designed by Spinogenix to help restore the brain connections and functions lost in Alzheimer’s disease and related neurodegenerative disorders.
  • Spinogenix anticipates that this NIH grant support will accelerate its efforts to bring this novel treatment to patients and potentially slow and reverse the fundamental process of synaptic degeneration at work in Alzheimer’s disease.
  • Spinogenix is advancing SPG302 as the first synaptic regenerative therapy in Alzheimer’s disease.
  • NIH previously awarded Spinogenix a phase one grant (number 1R43AG058278) for its research and development of this unique treatment for Alzheimer’s patients.

Royal Canin North America Announces Launch of SKINTOPIC™ to Help in the Management of Canine Atopic Dermatitis

Retrieved on: 
Monday, January 16, 2023
Smoky Hills PBS, University, Immunity, Royal Canin, University of Zurich, Itch, Veterinarian, Trial of the century, Quality of life, Dog, PMID, DMV, Skin, Antioxidant, Diagnosis, General practice, Prevalence, Diet, Atopic dermatitis, Dermatology, Clinical trial, Science, PMCID, PETS, Nutrient, International Task Force on Euthanasia and Assisted Suicide, Health, Vaccine, Veterinary medicine, Pharmaceutical industry

ST. CHARLES, Mo., Jan. 16, 2023 /PRNewswire/ -- Royal Canin North America, a global leader in pet health nutrition, has announced the launch of SKINTOPIC™, a new diet for the management of canine atopic dermatitis, a chronic pruritic skin disease in which dogs are hypersensitive to environmental allergens. A recent clinical trial demonstrated that precise nutrition can reduce itch and medication reliance in the treatment of atopic dermatitis. The launch of SKINTOPIC™ will help support vets in achieving better long-term management and improved quality of life for dogs suffering from atopic dermatitis.1

Key Points: 
  • A recent clinical trial demonstrated that precise nutrition can reduce itch and medication reliance in the treatment of atopic dermatitis.
  • The diet features include support of sensitive skin, improvement of quality of life through itch management and support of a strong skin barrier and immunity.
  • "We are proud to introduce SKINTOPIC™, a nutritional solution for the management of atopic dermatitis, backed by robust science.
  • We are confident this unique diet will help veterinarians provide better outcomes in atopy management."

FDA Releases Draft Over-the-Counter Hearing Aid Regulation

Retrieved on: 
Tuesday, October 19, 2021
People, NHIS, Arbitrage, PMCID, Epidemiology, Hearing loss, National, Hearing aid, Ear, Risk, Kool-Aid, NHANES, Association, Technology, Depression, Ageing, COVID-19, HIA, Person, News, Diagnosis, Patient safety, Use, Communication, Human, OTC, Statistics, Adult, Bluetooth, National Institutes of Health, Dementia, Public policy, FDA, Facebook, Education, Rechargeable battery, National Institute, National Health, Telephone, National Health Interview Survey, National Institute on Deafness and Other Communication Disorders, Hearing, Deafness, GLOBE, Atlantic Coastal Cooperative Statistics Program, Falls, Industry, Healthy People program, JAMA Otolaryngology–Head & Neck Surgery, Blog, Happiness, Population, Loss, Medicare, PSAP, Pharmaceutical industry, Dentistry, Personal protective equipment, Health insurance, Life insurance, Public relations

Hearing aids: Medical devices for people with hearing loss, most frequently prescribed by a hearing health professional and customized to fit and adjusted to discern sounds in all listening situations.

Key Points: 
  • Hearing aids: Medical devices for people with hearing loss, most frequently prescribed by a hearing health professional and customized to fit and adjusted to discern sounds in all listening situations.
  • Implants: Cochlear implant solutions, or bone-anchored hearing systems, that are designed for those with severe-to-profound hearing loss.
  • OTC hearing aids will be self-fitting and designed for adults with mild to moderate hearing loss.
  • In contrast, prescription hearing aids are customized, meaning a hearing health professional will test and identify your level of hearing loss and customize your hearing aids to optimize your hearing.

CooperVision Launches New Myopia Education Campaign for U.S. Parents

Retrieved on: 
Tuesday, October 12, 2021
Freedom, PMID, Prevalence, Lens (anatomy), Workforce, Genomics, SAN, COVID-19, CooperVision, Parent, British Academy Film Awards, Multimedia, The Cooper Companies, Astigmatism, Fertility, Presbyopia, JAMA Ophthalmology, FDA, Ophthalmology, Health, Quality of life, Lens, America's Best Contacts & Eyeglasses, Woman, Awareness, Learning, NYSE, Ageing, Dioptre, Imagen Awards, Disease, PMCID, Reyes, Cooper, Tutoring, Pharmaceutical industry, Toy, Film, Telescopic sight

SAN RAMON, Calif., Oct. 12, 2021 /PRNewswire/ -- CooperVision, a global leader in myopia management, today announced a new U.S. education initiative called "Take Control: Myopia & You" to increase awareness of the disease and encourage parents to schedule eye exams for their young children.

Key Points: 
  • SAN RAMON, Calif., Oct. 12, 2021 /PRNewswire/ -- CooperVision, a global leader in myopia management, today announced a new U.S. education initiative called "Take Control: Myopia & You" to increase awareness of the disease and encourage parents to schedule eye exams for their young children.
  • "Now we're encouraging additional parents to act by learning more and having these conversations with their eye doctor.
  • In addition to celebrity spokespeople, the omnichannel "Take Control: Myopia & You" campaign will feature notable eye care professionals.
  • 1 Holden et al, - Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050.